Navigation Links
Role of a key enzyme in reducing heart disease identified
Date:10/24/2007

Virginia Commonwealth University researchers have identified the role of a key enzyme called CEH in reducing heart disease, paving the way for new target therapies to reduce plaques in the arteries and perhaps in the future, help predict a patients susceptibility to heart disease.

Furthermore, unlike currently available therapies, which prevent or reduce the formation of new plaques, increasing CEH may also reduce existing plaques.

Heart disease results from the formation of plaques in the coronary artery, which supplies blood to the heart. Plaques form when monocytes, which are cells from the blood, enter the wall of the artery and consume large amounts of the bad cholesterol, or LDL. The monocytes then become artery-clogging foam cells. The only way for foam cells to get rid of their cholesterol is to make it available to HDL, or good cholesterol, for removal. A key enzyme present in the foam cells called cholesteryl ester hydrolase (CEH) regulates the amount of cholesterol that can be removed by HDL.

In this study, led by Shobha Ghosh, Ph.D., an associate professor of internal medicine, pulmonary division in the VCU School of Medicine, the team examined, for the first time, how cells in the artery wall make cholesterol available for removal by HDL. Using transgenic mice, which were fed a high fat and cholesterol-rich diet, the team was able to show that by increasing the removal of cholesterol from the artery clogging foam cells, the mice with the human gene for CEH developed significantly less heart disease.

Currently the emphasis for managing heart disease is on reducing the bad cholesterol or LDL in the circulation. Our study demonstrates that if you can increase the removal of cholesterol from the plaques, even without changing the LDL levels, there is still a significant reduction in the plaques, said Ghosh.

These findings not only change the current thinking of managing heart disease but also clearly open avenues for the development of new therapies. By identifying CEH as a new therapeutic target, we expect that in the future patients with heart disease will have more options to aggressively treat heart disease. In addition, by determining the levels of CEH in human blood cells, we hope to be able to predict susceptibility to heart disease in the future, she said.

According to Ghosh, the team focused their efforts on the examination of macrophage foam cells, which are responsible for storing large amounts of cholesterol and lead to the clogging of the arteries by forming plaques. The findings appear in the October print issue of the Journal of Clinical Investigation.

The team is actively exploring the mechanisms underlying CEH regulation and to determine how its activity can be increased in order to reduce heart disease.


'/>"/>

Contact: Sathya Achia-Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Enzyme may be target for obesity drugs
2. Researchers trick Alzheimers Enzyme
3. Enzyme stimulates growth of adult stem cells
4. Enzyme may aid hold back disease
5. Coenzyme Q10 may reduce risk of Parkinsons disease
6. Enzyme help destroy cancer cell
7. Key enzyme protects against Alzheimers
8. Enzyme Associated with Memory
9. Enzyme Associated With Memory
10. Brain Enzyme Found To Regulate Weight
11. New Enzyme Identified For Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... FCPX LUT Monochromatic Volume 2 is an ... easily add washed color grades to footage. A LUT is a Lookup Table that ... to the corresponding color indicated by the table. This pack comes with 60 different ...
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon ... all over the country. , Outdoor running increases exposure to ultraviolet radiation, a ... increased risk of melanoma, and only half may be adequately protecting themselves with ...
(Date:8/21/2017)... ... , ... PIXACORE , an independent full-service agency with a decade of ... the year by MM&M. , This is the first time PIXACORE has made the ... agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic ...
(Date:8/21/2017)... ... 21, 2017 , ... Project Hero today announced ... a multi-million dollar partnership commitment to support Project Hero’s efforts to help ... injuries (TBI) over the next year. , Optum’s partnership will help support ...
(Date:8/20/2017)... Texas (PRWEB) , ... August 20, 2017 , ... ... that the HIPAA ComplyPAK™ Compliance Management System has assisted multiple clients ... of Certified Public Accountants, Service Organization Control Level 2 (AICPA SOC Level 2), ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)...  Life Flight Network and PeaceHealth Oregon Network announced they ... and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Flight Network work collaboratively to move patients who require the ... time sensitive emergency exists. ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: